SYMPTOMS

long-term reduction in the frequency and severity of dysphagia^1,2

Reduction in DSQ score: 64% at week 24 and 81% at week 52^a

LSM change from baseline

0
-5
-10
-15
-20
-25
-30
-35

24-Week Placebo-Controlled
Treatment Period 28-Week Extended Active
Treatment Period

0
4^b
Part B
Coprimary Endpoint at Week 24
Week
24
Part B-C
Secondary Endpoint at Week 52
52

16%
Reduction
(-6 points)

31%
Reduction
(-12 points)

41%
Reduction
(-13.9 points)

Patients in the placebo arm
were switched to DUPIXENT at Week 24

~1.6x GREATER REDUCTION
at Week 24 with DUPIXENT
vs placebo

64%
Reduction
P<0.0001
(-23.8 points)

78%
Reduction
(-27.3 points)

81%
Reduction
(-30.3 points)

Placebo (n=79) DUPIXENT (n=80) Switch to DUPIXENT (n=24) DUPIXENT (n=54)

Part A (Coprimary Endpoint at Week 24)

Week 4: 9-point reduction (28%) from baseline with DUPIXENT (n=42) vs 4-point reduction (11%) with placebo (n=39)
Week 24: 21.9-point reduction (69%) from baseline with DUPIXENT (n=42) vs 9.6-point reduction (32%) with placebo (n=39) (P<0.001)

Part A-C (Secondary Endpoint)

Week 52: 23.4-point reduction (76%) from baseline after 52 weeks of treatment with DUPIXENT (n=29)
Week 52: 21.7-point reduction (66%) from baseline after switching to DUPIXENT from placebo at Week 24 (n=23)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

Week 4 assessment is a post hoc analysis; results are descriptive.

^aTotal biweekly DSQ scores range from 0 to 84; higher scores indicate greater frequency and severity of dysphagia.

LSM, least squares mean.

The Dysphagia Symptom Questionnaire (DSQ)³

A patient-reported assessment that measures the frequency and severity of dysphagia over a 14-day period; higher score indicates greater frequency and severity of dysphagia

long-term reduction in the frequency and severity of dysphagia1,2

Part A (Coprimary Endpoint at Week 24)

Part A-C (Secondary Endpoint)

The Dysphagia Symptom Questionnaire (DSQ)3

long-term reduction in the frequency and severity of dysphagia^1,2

The Dysphagia Symptom Questionnaire (DSQ)³